Literature DB >> 11052844

Abnormal glucose tolerance, not small vessel diameter, is a determinant of long-term prognosis in patients treated with balloon coronary angioplasty.

Y Otsuka1, S Miyazaki, H Okumura, S Yasuda, S Daikoku, I Morii, Y Sutani, Y Goto, H Nonogi.   

Abstract

AIMS: We sought to find out what factors are important for long-term prognosis, the small vessel itself or abnormal glucose tolerance, in patients treated with coronary angioplasty.
BACKGROUND: Patients with coronary artery disease with diabetes mellitus often show diffuse and small coronary artery narrowing. Impaired glucose tolerance has also been reported to be a risk factor for cardiovascular disease.
METHODS: Among 584 patients who underwent first elective balloon coronary angioplasty, diabetes mellitus and impaired glucose tolerance were present in 197 patients. Large and small vessels were defined by reference vessel diameter before coronary angioplasty as either larger or smaller than 2.5 mm. Patients were categorized into the following four groups: 175 patients with normal glucose tolerance and reference diameter <2.5 mm (group SN), 212 patients with normal glucose tolerance and reference diameter greater than or = 2.5 mm (group LN), 101 patients with abnormal glucose tolerance and reference diameter <2.5 mm (group SD), and 96 patients with abnormal glucose tolerance and reference diameter greater than or = 2.5 mm (Group LD). The cardiac events were compared for a period of 8 years after coronary angioplasty among the four groups.
RESULTS: There was no difference in the percentage diameter stenosis immediately after coronary angioplasty among the four groups. However, group SD showed unfavourable prognosis despite similar minimal lumen diameter after coronary angioplasty compared with group SN. Event-free survival curve of group LD showed a sudden drop approximately 5 years after the coronary angioplasty. In multivariate analysis, the cardiac events were associated with the presence or absence of abnormal glucose tolerance. Furthermore, patients with bad glycaemic control (HbA1c>6.0%) at index coronary angioplasty showed worse event free survival than those with good glycaemic control.
CONCLUSIONS: An important determinant for long-term prognosis after coronary angioplasty is a presence of abnormal glucose tolerance per se and not small vessel diameter.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11052844     DOI: 10.1053/euhj.2000.2181

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  6 in total

1.  Influence of diabetes on >10-year outcomes after percutaneous coronary intervention.

Authors:  Takatoshi Kasai; Katsumi Miyauchi; Kan Kajimoto; Naozumi Kubota; Takeshi Kurata; Hiroyuki Daida
Journal:  Heart Vessels       Date:  2008-05-17       Impact factor: 2.037

2.  Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart.

Authors:  M Bartnik; L Rydén; K Malmberg; J Ohrvik; K Pyörälä; E Standl; R Ferrari; M Simoons; J Soler-Soler
Journal:  Heart       Date:  2006-08-11       Impact factor: 5.994

Review 3.  How to revascularize patients with diabetes mellitus: bypass or stents and drugs?

Authors:  Albrecht Elsässer; Helge Möllmann; Holger M Nef; Christian W Hamm
Journal:  Clin Res Cardiol       Date:  2006-02-27       Impact factor: 5.460

4.  The effects of an exercise program on anthropometric, metabolic, and cardiovascular parameters in obese children.

Authors:  Yun Hee Lee; Young Whan Song; Hae Soon Kim; Sun Young Lee; Hee Seong Jeong; Sang-Hoon Suh; Jin Kyoung Park; Jo Won Jung; Nam Su Kim; Chung Il Noh; Young Mi Hong
Journal:  Korean Circ J       Date:  2010-04-23       Impact factor: 3.243

Review 5.  Obesity and cardiovascular disease.

Authors:  Paul Poirier; Robert H Eckel
Journal:  Curr Atheroscler Rep       Date:  2002-11       Impact factor: 5.113

Review 6.  The role of glycoprotein IIb/IIIa-receptor antagonists in diabetics.

Authors:  Kurt Huber
Journal:  J Thromb Thrombolysis       Date:  2003-04       Impact factor: 2.300

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.